Moreover, the combination of anti-HER2 agents with immunotherapy (i.e., pembrolizumab plus trastuzumab, trastuzumab emtansine plus atezolizumab and avelumab), despite disappointing clinical trial outcomes, suggests a synergistic effect in HER2-positive advanced breast cancer [47,48]. The gene discussed is ERBB2; the disease is breast cancer.